Female Health (NASDAQ:VERU) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright set a $5.00 price objective on Female Health and gave the company a “buy” rating in a research note on Thursday, May 10th. ValuEngine upgraded Female Health from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st.
Female Health (NASDAQ:VERU) last posted its earnings results on Wednesday, May 9th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $2.57 million for the quarter, compared to analysts’ expectations of $7.60 million. Female Health had a negative return on equity of 21.72% and a negative net margin of 87.78%. sell-side analysts anticipate that Female Health will post -0.23 earnings per share for the current fiscal year.
In other news, Director Harry Fisch acquired 24,000 shares of Female Health stock in a transaction on Wednesday, March 7th. The stock was bought at an average price of $1.62 per share, for a total transaction of $38,880.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mitchell Shuster Steiner acquired 20,000 shares of Female Health stock in a transaction on Tuesday, March 6th. The stock was purchased at an average price of $1.50 per share, with a total value of $30,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 119,000 shares of company stock valued at $210,980. 37.00% of the stock is owned by company insiders.
About Female Health
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with MarketBeat.com's FREE daily email newsletter.